Literature DB >> 23933656

Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia.

H S Lindgren1, D Rylander, H Iderberg, M Andersson, S S O'Sullivan, D R Williams, A J Lees, M A Cenci.   

Abstract

The transcription factor ΔFosB is a mediator of maladaptive neuroplasticity in animal models of Parkinson's disease (PD) and L-DOPA-induced dyskinesia. Using an antibody that recognizes all known isoforms of FosB and ΔFosB, we have examined the expression of these proteins in post-mortem basal ganglia sections from PD patients. The patient cases were classified as being dyskinetic or non-dyskinetic based on their clinical records. Sections from neurologically healthy controls were also included in the study. Compared to both controls and non-dyskinetic cases, the dyskinetic group showed a higher density of FosBFosB-immunopositive cells in the posterior putamen, which represents the motor region of the striatum in primates. In contrast, the number of FosBFosB-positive cells did not differ significantly among the groups in the caudate, a region primarily involved with the processing of cognitive and limbic-related information. Only sparse FosBFosB immunoreactivity was found in the in the pallidum externum and internum, and no significant group differences were detected in these nuclei. The putaminal elevation of FosBFosB-like immunoreactivity in patients who had been affected by L-DOPA-induced dyskinesia is consistent with results from both rat and non-human primate models of this movement disorder. The present findings support the hypothesis of an involvement of ΔFosB-related transcription factors in the molecular mechanisms of L-DOPA-induced dyskinesia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 23933656     DOI: 10.3233/JPD-2011-11068

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  13 in total

1.  Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.

Authors:  Lisa F Potts; Eun S Park; Jong-Min Woo; Bhagya L Dyavar Shetty; Arun Singh; Steven P Braithwaite; Michael Voronkov; Stella M Papa; M Maral Mouradian
Journal:  Ann Neurol       Date:  2015-03-27       Impact factor: 10.422

2.  Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.

Authors:  Kathy Steece-Collier; Timothy J Collier; Jack W Lipton; Jennifer A Stancati; Mary E Winn; Allyson Cole-Strauss; Rhyomi Sellnow; Melissa M Conti; Natosha M Mercado; Eduardo A Nillni; Caryl E Sortwell; Fredric P Manfredsson; Christopher Bishop
Journal:  Exp Neurol       Date:  2020-05-05       Impact factor: 5.330

3.  Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice.

Authors:  José-Rubén García-Montes; Oscar Solís; Juan Enríquez-Traba; Irene Ruiz-DeDiego; René Drucker-Colín; Rosario Moratalla
Journal:  Mol Neurobiol       Date:  2018-09-27       Impact factor: 5.590

4.  A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB Expression.

Authors:  Michael Feyder; Erik Södersten; Emanuela Santini; Vincent Vialou; Quincey LaPlant; Emily L Watts; Giada Spigolon; Klaus Hansen; Jocelyne Caboche; Eric J Nestler; Gilberto Fisone
Journal:  Biol Psychiatry       Date:  2014-07-28       Impact factor: 13.382

Review 5.  Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications.

Authors:  M Angela Cenci
Journal:  Front Neurol       Date:  2014-12-15       Impact factor: 4.003

Review 6.  Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?

Authors:  Daniella Rylander Ottosson; Emma Lane
Journal:  Front Cell Neurosci       Date:  2016-02-08       Impact factor: 5.505

Review 7.  On the neuronal circuitry mediating L-DOPA-induced dyskinesia.

Authors:  M Angela Cenci; Henrik Jörntell; Per Petersson
Journal:  J Neural Transm (Vienna)       Date:  2018-04-27       Impact factor: 3.575

Review 8.  Gut Microbial Metabolites in Parkinson's Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment.

Authors:  Yixuan Liang; Li Cui; Jiguo Gao; Mingqin Zhu; Ying Zhang; Hong-Liang Zhang
Journal:  Mol Neurobiol       Date:  2021-04-06       Impact factor: 5.590

9.  Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats.

Authors:  T Fieblinger; L Zanetti; I Sebastianutto; L S Breger; L Quintino; M Lockowandt; C Lundberg; M A Cenci
Journal:  Sci Rep       Date:  2018-07-03       Impact factor: 4.379

Review 10.  Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression.

Authors:  Giada Spigolon; Gilberto Fisone
Journal:  J Neural Transm (Vienna)       Date:  2018-02-02       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.